Bristol Myers to acquire Mirati Therapeutics for $58 per share 17:42 BMY Bristol Myers $56.66 / +0.24 (+0.43%) , MRTX Bristol Myers Squibb (BMY) and Mirati Therapeutics (MRTX) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8B.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.